It is hypothesized that T-cell checkpoint inhibition with MGA012, combined with activation and enhancement of redirected T-cell killing with MGD009, could mediate greater anti-tumor activity than either agent alone in patients with B7-H3 expressing solid tumors. This evidence concerns the gene CD276 and neoplasm.